Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea

Journal of Hepatology

Volumn 35, Issue 1, 2001, Pages 92-98

  Paik, Yong Han ^a   Chung, Hyo Young ^b   Ryu, Wang Shick ^c   Lee, Kwan Sik ^a   Lee, Ji Sook ^b   Kim, Jung Hee ^b   Lee, Chun Kyun ^a   Chon, Chae Yoon ^a   Moon, Young Myoung ^a   Han, Kwang Hyub ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Chronic hepatitis B; Hepatitis B virus DNA polymerase; Lamivudine; YMDD mutant

Indexed keywords

LAMIVUDINE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENDEMIC DISEASE; FEMALE; GENE AMPLIFICATION; HEPATITIS B; HUMAN; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SOUTH KOREA; VIRUS RESISTANCE;

ADULT; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; KOREA; LAMIVUDINE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

EID: 0034940480     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00065-4     Document Type: Article

References (32)

1. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dedioxy-3′-thiacytidine and related analogues
2. Biochemical pharmacology of (+)-and (-)-2′,3′-dideoxy-3′-thiacytidine as a anti-hepatitis B virus agents
3. Anti-human immunodeficiency virus and anti-hepatitis B virus activities and toxicities of the enantiomers of 2′-deoxy-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro
4. Phosphatidyl-2′,3′-dideoxy-3′ thiacytidine: Synthesis and activity in hepatitis B and HIV-1 infected cells
5. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
6. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
7. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
8. Lamivudine resistance in immunocompetent chronic hepatitis B
9. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2′-deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA
10. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
11. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation of therapy
12. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine
13. Long-term therapy of chronic hepatitis B with lamivudine
14. Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus
15. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy
16. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
17. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
18. Avoiding false positives with PCR
19. A one year trial of lamivudine for chronic hepatitis B
20. Lamivudine as initial treatment for chronic hepatitis B in the United States
21. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
22. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
23. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
24. Epidemiologic study of hepatitis B in pregnant Korean women
25. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
26. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product
27. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
28. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycitidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine
29. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
30. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants
31. Fidelity of HIV-1 reverse transcriptase copying a hypervariable region of the HIV-1 env gene
32. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B